Back to the archive
11/01/2016| Angelini Fine Chemicals: new synthesis technologies to broaden the offer

Michele Crocetta, Marketing & Business Development Manager of Angelini Fine Chemicals, talks about Fine Chemicals, a plant specialised in manufacturing pharmaceutical active principles and advanced intermediate products. 

 


1. Fine Chemicals is Angelini’s raw materials division. What does it do in particular?
In the Fine Chemicals & Export Department we deal with the manufacture of active principles (API) in the field of pharmaceuticals for human use. Our division is a member of Aschimfarma, which includes firms belonging to the sector of pharmaceutical raw materials, in particular active principles and intermediates. Fifty-four Italian firms and multinationals belong to Aschimfarma; they generate a turnover of 2.3 thousand million euro and manufacture chemical-organic substances obtained by industrial processes with a high technological content, both in the phase of development and of production. Italy plays a leading role on the world market and exports more than 85% of its production to more than 90 countries. Firms that are members of Aschimfarma are known for their strict application of Good Manufacturing Standards, which enables them to achieve the highest levels of quality and reliability.

2. What are your excellent products? 
The plant in Aprilia is a leader in the manufacture of Trazodone (antidepressant), Benzydamine (anti-inflammatory), Oxolamine (cough suppressant), Metaxalone (muscle relaxant) and Acamprosate (molecule for treating alcohol dependence). Some of these active principles are created for the manufacture of Angelini medicaments such as, for example: Trittico (Trazodone), Tantum Verde (Benzidamine) and Perebron (Oxolamine); the others are sold to other multinationals in the pharmaceutical world.
A turnover of 27 million/€ is forecast for 2015.

3. A recent article in the Sole 24Ore newspaper states that the United States market on its own is 38% of the world market: what is the presence of Fine Chemicals in the USA? Who are your customers? How much of your production stays in Italy and how much is exported? 
Our main customers are Teva, Pfizer and Mylan. We also have other important players on the market such as, for example, Impax, Iwaki, Boehringer-Ingelheim, MSD, Sanofi-Aventis, Sun Pharmaceutical. About 30% of the production is used within the Angelini group, the rest is shipped to customers located in various parts of the world.
Our main market is the USA, where we have been present since 1979 with Trazodone and with which we can now boast a position of market leader, with a share of 90%. This is all thanks to the excellent business relations established with customers over the years and to the quality and reliability of our firm. This situation includes the recent passing of the inspection by the FDA, the US regulatory body.

4. What do your marketing activities with customers consist of?
Constant contacts, visits to and participation in trade fairs such as, for example, INFORMEX and DCAT (USA), CPHI Worldwide. The latter was held in Madrid last October and was attended by colleagues with different posts from the plants in Ancona, Aprilia and Santa Palomba.
The market is constantly monitored so as to seize business opportunities. We also try to develop synergisms with the Pharmaceutical Hub as was done, for example, for Erdosteine (mucolytic), a product for which the licence for the countries of Eastern Europe was granted to Angelini by Recipharm and for which we are going to start manufacturing the active principle.

5. What are the development strategies of Fine Chemicals for the near future?
Angelini Fine Chemicals operates in a competitive, complex and global scenario. For a firm to be a success in this sector it has to combine high managerial skills with constant technological innovations.
We have identified new molecules, such as Esto (cerebral tonic), for the Italian and Asian market, and Erdosteine (mucolytic), for the countries of Eastern Europe. With regard to Custom Synthesis, that is to say the work dedicated to the development of new molecules that have not yet been registered and are therefore not present on the market, we are starting to cooperate with a US Biotech firm for the manufacture and sale of a molecule prescribed in oncology.
Lastly, we are examining new business opportunities related to the new synthesis technologies, which will enable Angelini both to increase the production capacity of the plant in Aprilia and to increase the potential for cooperation with new partners and new markets.

Back to the archive